Drug intelligence / Profile preview

Germ-X

Development stage: Unknown
Lead developer: Vi Jon
Administration: Topical

Overview

**Germ-X** is a marketed topical Ayurvedic hand-antiseptic product from Ergon Pharmaceuticals. The manufacturer identifies its reference ingredient as Sumatra benzoin under B.N.A.F. and states that it is intended for hand sanitizing to decrease bacteria on the skin; users apply sufficient product to the hands and rub until dry. The public product listing does not disclose a defined molecular composition, pharmacologic target, or target-specific mechanism. ([ergonbd.info](https://ergonbd.info/))

Brand names: Germ-X

Beyond the preview

Go deeper on Germ-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Germ-X.

Explore the full profile